PoeweWMahlknechtP.Pharmacologic treatment of motor symptoms associated with Parkinson disease. Neurol Clin. 2020;38:255-267. doi:10.1016/j.ncl.2019.12.002
2.
MüllerTMöhrJD.Recent clinical advances in pharmacotherapy for levodopa-induced dyskinesia. Drugs. 2019;79:1367-1374. doi:10.1007/s40265-019-01170-5
3.
GiacinoJTWhyteJBagiellaE, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366:819-826. doi:10.1056/NEJMoa1102609
4.
deVriesTDentisteAHandiwalaLJacobsD.Bioavailability and pharmacokinetics of once-daily amantadine extended-release tablets in healthy volunteers: results from three randomized, crossover, open-label, phase 1 studies. Neurol Ther. 2019;8:449-460. doi:10.1007/s40120-019-0144-1
5.
CedarbaumJM.Clinical pharmacokinetics of anti-Parkinsonian drugs. Clin Pharmacokinet. 1987;13:141-178. doi:10.2165/00003088-198713030-00002
6.
SomaniSKDegelauJCooperSLGuayDRPEhresmanDZaskeD.Comparison of pharmacokinetic and safety profiles of amantadine 50- and 100-mg daily doses in elderly nursing home residents. Pharmacotherapy. 1991;11:460-466. doi:10.1002/j.1875-9114.1991.tb02661.x
7.
CattoniJParekhR.Acute respiratory distress syndrome: a rare presentation of amantadine toxicity. Am J Case Rep. 2014;15:1-3. doi:10.12659/AJCR.889931
8.
CookPEDermerSWMcGurkT.Fatal overdose with amantadine. Can J Psychiatry. 1986;31:757-758. doi:10.1177/070674378603100814
9.
KeyserLAKarlMNafzigerANBertinoJSJr.Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med. 2000;160:1485-1488. doi:10.1001/archinte.160.10.1485
